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respiratory syndrome.
Background. Severe acute respiratory syndrome (SARS) is
a newly emerged infection from a novel coronavirus (SARS-
CoV). Apart from fever and respiratory complications, acute re-
nal impairment has been observed in some patients with SARS.
Herein, we describe the clinical, pathologic, and laboratory fea-
tures of the acute renal impairment complicating this new viral
infection.
Methods. We conducted a retrospective analysis of the plasma
creatinine concentration and other clinical parameters of the
536 SARS patients with normal plasma creatinine at first clin-
ical presentation, admitted to two regional hospitals following
a major outbreak in Hong Kong in March 2003. Kidney tissues
from seven other patients with postmortem examinations were
studied by light microscopy and electron microscopy.
Results. Among these 536 patients with SARS, 36 (6.7%) de-
veloped acute renal impairment occurring at a median duration
of 20 days (range 5–48 days) after the onset of viral infection
despite a normal plasma creatinine level at first clinical pre-
sentation. The acute renal impairment reflected the different
prerenal and renal factors that exerted renal insult occurring
in the context of multiorgan failure. Eventually, 33 SARS pa-
tients (91.7%) with acute renal impairment died. The mortality
rate was significantly higher among patients with SARS and
acute renal impairment compared with those with SARS and
no renal impairment (91.7% vs. 8.8%) (P < 0.0001). Renal tis-
sues revealed predominantly acute tubular necrosis with no ev-
idence of glomerular pathology. The adjusted relative risk of
mortality associated with the development of acute renal im-
pairment was 4.057 (P < 0.001). By multivariate analysis, acute
respiratory distress syndrome and age were the most significant
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independent risk factors predicting the development of acute
renal impairment in SARS.
Conclusion. Acute renal impairment is uncommon in SARS
but carries a high mortality. The acute renal impairment is likely
to be related to multi-organ failure rather than the kidney
tropism of the virus. The development of acute renal impair-
ment is an important negative prognostic indicator for survival
with SARS.
A novel mysterious pneumonia appeared in the
Guangdong Province of China in November 2002. It did
not receive much attention until widespread outbreak oc-
curred, first in southern Asia and then across the world.
In March 2003, the World Health Organization (WHO)
coined the new disease as severe acute respiratory syn-
drome (SARS). SARS is a highly contagious and pre-
dominantly pneumonic illness caused by a novel coron-
avirus (CoV) now commonly known as SARS-CoV [1,
2]. Since its recognition in March 2003, SARS has spread
to 30 countries and has infected over 8000 people, result-
ing in almost 700 deaths worldwide [3]. In Hong Kong,
1755 subjects were infected and 299 died. Over 25% of
the victims were health care workers, and the fear of this
disease had created devastating socioeconomic effects in
Hong Kong and worldwide.
Although acute respiratory failure due to diffuse alve-
olar damage was associated with the highest mortality [4],
lungs were not the only organs involved. Severe diarrhea
and hepatic dysfunction were the presenting symptoms
in some patients with SARS [5]. Among patients with
confirmed CoV-associated SARS, we encountered a sig-
nificant number of patients with acute renal dysfunction.
Some even progressed to renal failure and required dial-
ysis. Herein, we describe the demographic, clinical, labo-
ratory, and radiologic features of this SARS cohort with
acute renal impairment [acute renal failure (ARF)] and
study any risk factor associated with the development of
ARF.
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METHODS
Patients and data collection
The analysis included all confirmed SARS cases
with normal plasma creatinine (normal range 60 to
120 lmol/L) at first clinical presentation, admitted to the
Princess Margaret Hospital and the Queen Mary Hos-
pital, Hong Kong, between March 1 and May 31, 2003.
SARS was initially diagnosed based on criteria issued by
the WHO [6]. The hospital records were reviewed fol-
lowing approval of the institutional ethical committee.
Additional radiologic and laboratory information were
retrieved from the hospital computerized Clinical Man-
agement System. Demographic data and symptom pro-
files were recorded in all patients by a standard form on
admission. Chest radiograph was mandatory with sup-
plementary chest computerized-axial tomography (CT)
when clinically indicated. Blood pressure, temperature,
and pulse rate were monitored regularly after admission.
Initial laboratory investigations included complete blood
count, arterial blood gas, lactate dehydrogenase (LDH),
creatine phosphokinase, liver, and renal function tests.
Serial monitoring of the laboratory profile was performed
according to the clinical progress of individual patient.
Chest radiograph was taken on alternate days. Either na-
sopharyngeal aspirates or nasal/throat swabs were taken
for CoV testing by polymerase chain reaction (PCR).
Paired sera were collected on admission and on day 14
for determination of a fourfold rise of IgG anti-CoV an-
tibodies.
Definitions
Acute renal impairment was defined as an elevation of
plasma creatinine by at least 30% of the baseline value on
admission (documented by three consecutive blood sam-
plings) or above 160 lmol/L following a normal plasma
creatinine on admission. Acute respiratory distress syn-
drome (ARDS) was defined according to the criteria of
the American-European Consensus Conference as an ill-
ness characterized by impaired oxygenation, with a ratio
of the partial pressure of arterial oxygen (PaO2) to the
fraction of inspired oxygen (FiO2) (≤200 mm Hg), re-
gardless of whether or how much positive end-expiratory
pressure is used to support, and the presence of bilateral
infiltrates on chest radiographs and pulmonary artery oc-
clusion pressure ≤18 mm Hg with no clinical evidence of
left atrial hypertension [7].
Dialysis treatment
For those patients who required subsequent dialysis
treatment for ARF, either peritoneal dialysis or hemofil-
tration was performed depending on the availability of
equipment. Indications for dialysis included increased
uremia, electrolyte and acid-base imbalance, and fluid
retention. Peritoneal dialysis was administered using
an acute peritoneal catheter. Hourly 1 L exchange of
peritoneal dialysate was performed manually. For blood
purification, pump-driven continuous venovenous
hemofiltration was used. The replacement solution con-
tained self-admixtured sodium bicarbonate and sodium
chloride solution. Citrate was used for anticoagulation.
Calcium chloride was infused through another central
line. The hourly ultrafiltration rate was set at 1500 mL
and the net ultrafiltration was adjusted by titrating
the volume of saline replacement administered via a
separate line.
Renal specimen
Due to the special infection-control precaution of han-
dling deceased subjects with SARS, postmortem exam-
ination was not performed routinely. Postmortem was
performed in a designated pathology laboratory. Kidney
specimens from autopsy of seven other SARS subjects
(not from the above study group) were retrieved for stan-
dard examination of light microscopy and electron mi-
croscopy.
Kidney tissues were further studied by in situ hybridiza-
tion for detection of SARS-CoV using techniques de-
scribed [8]. Briefly, the probe was labeled with digox-
igenin by nick translation (DIG-Nick Translation Mix)
(Roche, Indianapolis, IN, USA). Cell-block preparations
from Vero cell culture with and without inoculation with
SARS-CoV were used as positive and negative controls,
respectively. The signal specificity was also assessed by
(1) digestion of the sections with RNase A, (2) omission
of the probes in the hybridization mixture, and (3) tissue
sections from three autopsy cases of non-SARS patients
were included as negative controls.
Statistics
We compared risk factors associated with ARF and
normal renal function with the v 2 or Fisher’s exact test
for categorical variables. Laboratory data were expressed
as median and range and analyzed with Mann-Whitney
test. Cox proportional hazards model was used in the
calculation of hazard ratio (relative risk) of mortality
and development of ARF for each risk factor. Significant
risk factors identified by univariate analyses were fur-
ther analyzed in multivariate model to identify indepen-
dent risk factors associated with the development of ARF.
Due to a relatively smaller population of SARS patients
with ARF as compared with those with normal renal
function, risk factors with P value less than 0.01, accompa-
nied with 99% confidence interval, was chosen as statisti-
cally significant level unless specified otherwise. The least
squares mean plasma creatinine and the time for doubling
the plasma creatinine concentration in different groups
of SARS with ARF were calculated from prediction
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polynomial equations of mixed linear model. We used the
standard SPSS 11.0 statistical package for all analyses.
RESULTS
Patient demographic data
During the study period, 544 patients with confirmed
SARS were admitted to the Princess Margaret and Queen
Mary Hospitals. Eight patients were excluded from the
study as they had chronic renal impairment due to chronic
glomerulonephritis or diabetes nephropathy. Among the
remaining 536 patients, thirty-six patients (25 males and
11 females) (6.7%) with a median age of 53.5 years (34
to 77) were subsequently found to have elevated plasma
creatinine levels during the later clinical course. The me-
dian time from the onset of viral infection to the develop-
ment of ARF in these 36 patients was 20 days (range, 5 to
48 days). The peak plasma creatinine levels ranged from
136 to 1083 lmol/L, with a median value of 274 lmol/L.
Fourteen of these 36 patients (39%) had plasma bicar-
bonate lower than 24 mmol/L (normal 24 to 26 mmol/L)
prior to or at the time of detection of ARF. Oliguria (urine
output <500 mL/day) occurred in half of these 36 pa-
tients. Those patients with ARF were older (P <0.001)
and had higher systolic blood pressure (P = 0.005) than
other SARS patients with no ARF. Comorbidity factors
included hypertension (10 patients), diabetes mellitus (5
patients), ischemic heart disease (2 patients), hepatitis B–
associated chronic hepatitis (one patient), bronchiectasis
(one patient), stroke (one patient), hypertrophic obstruc-
tive cardiomyopathy (one patient), and sinoatrial node
dysfunction (one patient).
Table 1. Various laboratory and clinical parameters of patients with acute renal impairment and normal kidney function
Renal impairment Normal renal function
Variable (N = 36) (N = 500) P value
Age years 53.5 (34–77) 38.0 (18–96) <0.001
Systolic blood pressure mm Hg 130.5 (105–200) 125.0 (96–210) 0.013
Diastolic blood pressure mm Hg 70.0 (54–100) 70.0 (40–109) 0.942
Hemoglobin g/dLa 14.0 (8.4–16.9) 13.2 (7.6–18) 0.035
White blood cells (×109/L)a 6.5 (1.8–16.3) 5.30 (1.55–27.3) 0.005
Neutrophil (×109/L)a 5.00 (0.8–15.5) 3.90 (0.7–26.3) 0.004
Lymphocyte (×109/L)a 0.80 (0.3–2.8) 0.80 (0.2–3.1) 0.556
Platelet (×109/L)a 151.0 (79–285) 163.0 (41–893) 0.671
Prothrombin time seconda 11.9 (10.2–14.1) 12.0 (0.4–120) 0.391
Activated partial thromboplastin time seconda 33.2 (23.3–87) 32.2 (14–120) 0.092
Plasma sodium mmol/La 132.0 (126–140) 134.0 (121–144) 0.001
Plasma potassium mmol/La 3.7 (2.8–6.1) 3.6 (2.2–8.1) 0.634
Plasma urea mmol/La 4.6 (1.8–16) 3.4 (0.3–18.6) <0.001
Plasma creatinine lmol/La 93.5 (48–128) 70.0 (40–123) <0.001
Plasma albumin g/La 34.0 (23–44) 38.0 (20–50) <0.001
Plasma alanine aminotranferase U/La 49.0 (12–193) 26.0 (3–587) 0.001
Plasma lactate dehydrogenase U/La 311.0 (148–990) 218.5 (30–1669) <0.001
Nadir hemoglobin g/dL 8.7 (3.4–15.5) 11.3 (3.9–15.8) <0.001
Nadir white blood cells (×109/L) 5.35 (1.8–10.5) 4.00 (0.8–20.5) 0.003
Nadir lymphocyte (×109/L) 0.30 (0.1–0.7) 0.40 (0–7.3) <0.001
Plasma peak creatine phosphokinase U/L 222.0 (26–22974) 96.0 (11–7154) <0.001
Symptomatic days before admission 1.0 (1–3) 3.0 (1–15) 0.071
aMeasurement at first admission.
Most of these 36 patients had fever on presentation
(97.2%). High temperature (≥39◦C) was observed in
22.2% of patients. Other common complaints included
palpitation (86.1%), chills (63.8%), malaise (66.7%),
cough (44.4%), dyspnoea (41.6%), anorexia (33.3%), and
myalgia (30.6%). Rigor only occurred in ten patients
(27.8%). Cough was usually nonproductive and only nine
patients (25%) had production of sputum. Other no-
table symptoms included headache (19.4%), dizziness
(13.8%), and diarrhea (13.8%). The clinical presentations
were similar to previous described [9]. The mean systolic
and diastolic blood pressures on admission blood pres-
sure were 136 mm Hg and 72.5 mm Hg, respectively. El-
evated systolic (>140 mm Hg) and diastolic (>90 mm
Hg) blood pressures were found in 12 (33.3%) and 3
(8.3%) patients, respectively. Five patients had systolic
blood pressure exceeding 160 mm Hg.
Laboratory findings
Semiquantitative urinalysis was performed in 26 pa-
tients when they developed ARF. Proteinuria by dip-
stick was found in 22 patients (84.6%). Heavy protein-
uria was not a common finding (trace in 11 patients, + in
seven patients, ++ in two patients, and +++ in three pa-
tients). The laboratory profiles on admission are shown in
Table 1. Notably, hyponatremia (sodium < 135 mmol/L)
was found in 28 patients (77.7%). Absolute neutropenia
was only found in four patients (11.1%) yet the major-
ity of the patients had lymphopenia (75.0%). In these
36 patients, the nadir hemoglobin and nadir leukocyte
counts fell to 8.7 g/dL (3.4 to 15.5) and 5.35 × 109/L
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Fig. 1. Serial measurement of plasma creatinine (expressed as median)
of these 36 severe acute respiratory syndrome (SARS) patients compli-
cated with acute renal failure (ARF).
(1.8 to 10.5), respectively. The nadir absolute neutrophil
and lymphocyte counts dropped to 3.95 × 109/L (0.8 to
9.9) and 0.3 × 109/L (0.1 to 0.7), respectively. At clinical
presentation, all patients had radiographic abnormalities
on chest radiograph. Among the 36 patients with ARF,
the right lung involvement was more prevalent than the
left lung (41.7% vs. 13.9%), which was similar to the
patients with normal renal function (47.8% vs. 26.6%)
(P = 0.332). However, the remaining patients with ARF
(44.4%) had significantly higher bilateral and diffuse in-
filtrations compared with SARS patients with normal re-
nal function (21.0%) (P = 0.002). Nasopharyngeal aspi-
rates or nasal/throat swabs were positive for CoV by PCR
analysis in 19 patients (52.7%) and another six patients
(16.7%) had detected IgG against CoV. SARS-CoV in-
fection was confirmed in the remaining 11 patients by
subsequent fourfold rise in antibody titer.
When compared with those with normal renal function
during the course of SARS, patients who subsequently
developed ARF had lower plasma sodium (P = 0.001)
and albumin (P < 0.001), elevated alanine aminotrans-
ferase (P = 0.001), and raised plasma LDH on admission
(P < 0.001). On the other hand, diastolic blood pres-
sure, hemoglobin on admission, lymphocyte count on
admission, platelet count on admission, prothrombin
time, activated partial thromboplastin time, plasma
potassium, and symptomatic days before admission did
not differ between two groups of patients. Patients who
subsequently developed ARF had higher peak plasma
creatine phosphokinase concentration after admission
(P < 0.001).
Plasma creatinine concentration
The serial median plasma creatinine of these 36 SARS
patients with ARF is shown in Figure 1. The median
duration from the onset of viral infection to the devel-
opment of ARF was 20 days (range, 5 to 48 days). The
least squares mean creatinine value over time for these
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Fig. 2. Plasma creatinine concentrations. (A) The least squares mean
plasma creatinine concentration over time for alive patients (N = 3)
and deceased patients (N = 33) deducted from polynomial equations of
mixed linear model. (B) The least squares mean plasma creatinine con-
centration deducted from polynomial equations of mixed linear model
for patients who died within 15 days (N = 12), within 15 to 30 days (N =
19), and after 30 days (N = 2). FU is the duration of hospitalization.
36 SARS patients with ARF is shown in Figure 2A. Pa-
tients who subsequent died (N = 33) had a progressive
rise of plasma creatinine and the doubling time for the
plasma creatinine value at admission was calculated to
be 18.3 days, using prediction equation of mixed linear
model. In contrast, those who were alive (N = 3) had a
predicted fall of plasma creatinine from day 10 after ad-
mission. Analysis of the serial measurements of plasma
creatinine among those 33 deceased patients is depicted
in Figure 2B. The rise of plasma creatinine was rapid
in those who succumbed early in their illness. Using a
prediction equation of mixed linear model, the average
times to double the plasma creatinine value on admis-
sion for those survived for less than 15 days and those
survived between 16 and 30 days after admission were
7.2 days and 20.6 days, respectively. Patients with ARF
who succumbed within 15 days after hospitalization had
lower plasma albumin (P < 0.01), higher plasma LDH
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(P < 0.01), and higher plasma creatine phosphokinase
(P < 0.01) on admission than those with ARF who suc-
cumbed only after day 15 from initial hospitalization.
Treatment protocol and other nonrenal complications
On admission, all patients were initially treated with
broad-spectrum antibiotics, including intravenous ce-
fepime (2 g three times a day) and oral clarithromycin
(500 mg twice a day) for 3 to 5 days to target bac-
terial pathogens incriminated in the etiology of severe
community-acquired pneumonia. Subsequently, 34 pa-
tients (94.4%) received intravenous ribavirin according
to a standard regime [10]. Corticosteroids were adminis-
tered in 34 patients (94.4%) when the chest radiograph
showed increasing infiltrates or the blood gases revealed
mild desaturation. The majority of them (31/36) also re-
ceived pulse dose of methylprednisolone. Percentage of
patients receiving ribavirin and corticosteroids did not
differ between patients with and without ARF (92% and
91.2%, respectively).
Seventy-two (13.4%) of our 536 SARS patients devel-
oped ARDS. Thirty-three (45.8%) of these 72 patients
also developed ARF. In contrast, only three (0.65%) of
the 464 SARS patients with no ARDS developed ARF
(Fisher’s exact test, P < 0.0001). Of the SARS patients
with ARF, 11.4% had raised plasma creatine phospho-
kinase (>1500 U/L). The percentage was significantly
higher than that of SARS patients with no ARF (1.1%)
(Fisher’s exact test, P = 0.002).
All 36 patients with ARF were cared in the intensive
care unit. Indications for admission included fluid reten-
tion, oxygen desaturation, or rising plasma creatinine.
Eighteen patients had profound hypotension necessitat-
ing inotropic support. Ten patients received acute sup-
portive dialysis: four by continuous hemofiltration and
the remaining six by peritoneal dialysis. The remaining
26 patients developed ARF late in their illness with estab-
lished multiorgan failure, including ARDS. Dialysis was
not performed in these patients in view of severe multior-
gan failure. Eventually, 33 SARS patients (91.7%) with
ARF died. The mortality rate was significantly higher
among patients with SARS and ARF compared with
those with SARS and no renal impairment (91.7% vs.
8.8%) (P < 0.0001).
Relative risk factors of mortality or development of ARF
in SARS
On univariate analysis, the risk factors associated with
mortality were age (P < 0001), systolic blood pressure
(P = 0.032), high leukocyte count on admission (P =
0.029), low nadir leukocyte count (P < 0.001), low nadir
lymphocyte count (P < 0.001), low plasma albumin on
admission (P < 0.001), raised alanine aminotransferase
(P = 0.004), the peak serum creatinine kinase phos-
Table 2. Risk factors of mortality in severe acute respiratory
syndrome (SARS) by univariate analysis
Relative risk (99% CI) P value
Use of inotropes 15.77 (7.539–32.99) <0.001
Acute renal impairment 16.91 (8.368–34.16) <0.001
Acute respiratory distress 10.28 (4.854–21.77) <0.001
syndrome
Systolic blood pressure 1.014 (0.997–1.031) 0.032
White blood cells 1.066 (0.988–1.150) 0.029
Lymphocyte count 0.529 (0.209–1.339) 0.077
Nadir white blood cells 1.160 (1.057–1.272) <0.001
Nadir lymphocyte count 0.016 (0.001–0.217) <0.001
Plasma albumin on admission 0.890 (0.841–0.942) <0.001
Peak plasma creatine 6.689 (1.699–26.34) <0.001
phosphokinase > 1500a
Plasma alanine aminotransferase 1.005 (1.001–1.009) 0.004
on admission
Age 1.049 (1.029–1.068) <0.001
aPatients with creatine phosphokinase less than 1500 serve as the reference
group.
Table 3. Independent risk factor predicting mortality in severe acute
respiratory syndrome (SARS) by multivariate analysis
Adjusted relative risk
(99% CI) P value
Acute renal impairment 4.057 (1.461–11.27) <0.001
Acute respiratory distress syndrome 3.286 (1.141–9.463) 0.004
Age 1.033 (1.008–1.058) 0.001
Plasma albumin on admission 0.936 (0.876–0.999) 0.009
phatase (P < 0.001), use of inotropes (P < 0.001), ARDS
(P < 0.001), and ARF (P < 0.001) (Table 2). Table 3 sum-
marizes independent risk factors predicting mortality in
SARS by multivariate analysis. On multivariate analysis,
only age, plasma albumin on admission, ARDS, and the
development of ARF were significant risk factors. The
adjusted relative risks of mortality associated with the
development of ARDS and ARF were 3.286 (P = 0.004)
and 4.057 (P < 0.001), respectively. A moderate correla-
tion was found between the development of ARDS and
ARF in the multivariate model for predicting mortality
in SARS (correlation coefficient r = 0.61, P < 0.001).
On univariate analysis, the risk factors associated with
the development of ARF in SARS patients were age
(P < 0.001), systolic blood pressure (P = 0.032), low
nadir leukocyte count (P = 0.029), low nadir lymphocyte
count (P = 0.006), low plasma albumin on admission (P <
0.001), raised alanine aminotransferase (P = 0.004), the
peak serum creatinine kinase phosphatase (P < 0.001),
the use of inotropes (P < 0.001), and the complication of
ARDS (P < 0.001) (Table 4). On multivariate analysis,
ARDS was the most significant independent risk factor
predicting the development of ARF in SARS (adjusted
relative risk 37.91 (99% CI 7.969 to 180.4) (P < 0.001)
(Table 5). As a strong correlation was found between the
use of inotropes and ARDS, it was not included in the
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Table 4. Risk factors of the development of acute renal impairment
in severe acute respiratory syndrome (SARS) by univariate analysis
Relative risk
(99% CI) P value
Use of inotropes 124.2 (19.01–811.4) <0.001
Acute respiratory distress syndrome 46.60 (9.800–221.6) <0.001
Systolic blood pressure 1.017 (0.997–1.038) 0.032
White blood cells 1.047 (0.943–1.164) 0.257
Lymphocyte count 0.717 (0.233–2.205) 0.446
Nadir white blood cells 1.115 (0.980–1.267) 0.029
Nadir lymphocyte count 0.039 (0.002–0.812) 0.006
Plasma albumin on admission 0.904 (0.842–0.971) <0.001
Peak plasma creatine phosphokinase 12.65 (3.039–52.64) <0.001
> 1500a
Plasma alanine transferase on 1.005 (1.001–1.010) 0.004
admission
Age 1.044 (1.019–1.069) <0.001
aPatients with creatine phosphokinase less than 1500 serve as the reference
group.
Table 5. Independent risk factor predicting the development of acute
renal impairment in severe acute respiratory syndrome (SARS) by
multivariate analysis
Adjusted relative risk
(99% CI) P value
Acute respiratory distress 37.91 (7.969–180.4) <0.001
syndrome
Age 1.037 (1.007–1.067) 0.001
multivariate model to avoid imprecise estimation of rel-
ative risk (correlation coefficient 0.79, P < 0.0001).
Renal pathology finding
The pathological findings of kidney specimens from
autopsy in another seven SARS subjects are summa-
rized in Table 6. Four patients had ARF despite a normal
plasma creatinine concentration on first clinical presen-
tation. Under light microscopy, some degree of benign
hypertensive nephrosclerosis and autolysis were noted in
most cases. However, glomerular pathology was not ob-
served in the kidneys. Acute tubular necrosis of varying
degrees was found in all seven renal specimens. In case
3 with comorbid disease of myelodysplastic syndrome,
abnormal myeloid infiltrate was noted in the kidney. No
interstitial infiltrate or interstitial nephritis was detected
in all other cases. Viral inclusion was not evident. Care-
ful ultrastructural examination of both glomerular and
tubular epithelial cells failed to reveal virus or viral-like
particles. Immunofluorescence studies on frozen sections
were not performed because of high infectivity, but no
electron-dense immune deposits were detected with ul-
trastructural examination. In situ hybridization failed to
demonstrate SARS-CoV in these seven kidney samples.
All seven cases demonstrated diffuse alveolar damage
in their lungs. Kidney specimens from the four subjects
who subsequently developed significant impairment of
renal function showed moderate to severe acute tubular
necrosis.
DISCUSSION
SARS is a new infectious disease with a formidable
morbidity and mortality. A wide range of nonrespira-
tory symptoms has subsequently been reported suggest-
ing other organ involvements including the liver and gas-
trointestinal tract during the course of the disease [4, 10,
11]. With the exception of a few chronic dialysis patients
complicated by SARS [12–14], impaired renal function
with raised plasma creatinine is not a common finding in
most SARS patients at the time of first clinical presenta-
tion. A preliminary study of 12 patients with SARS who
developed ARF reports a high mortality rate of 77% [ab-
stract; Tsai HB, et al, J Am Soc Nephrol 14:513A, 2003).
In our retrospective analysis of 536 SARS patients,
6.7% of this cohort had raised plasma creatinine con-
centration during the later course of the infection despite
normal value at first presentation. Although more sophis-
ticated assessment of renal function was not performed
due to the high infectivity of body fluid, ARF with sig-
nificant kidney dysfunction was suggested by the peak
median plasma creatinine concentration of 274 lmol/L.
More intriguingly, these patients only developed ARF
at a median duration of 20 days from the onset of viral
infection that coincided with the late viremic or the hy-
perimmune response phase of the infection [15]. Hence,
it is totally not surprising that ARF was not reported in
previous studies in which only clinicopathologic features
at first clinical presentation were presented [1, 4, 16–18].
Patients who subsequently developed renal impairment
had clinical presentations similar to the symptomatology
of SARS patients in previous reports. Severe diarrhea, an
important symptom in a patient cohort that might have
acquired the infection through the contamination of the
sewage systems [16], only occurred in 13.8% of our co-
hort.
The etiology of ARF is likely to be diverse and multi-
factorial. Broad-spectrum antibiotics, which were some-
times administered in high doses, may cause interstitial
nephritis. It should be clarified that identical antibiotic
regimes were given to our two groups of SARS patients
(with and without ARF). Eosinophilia was not detected
in patients with ARF. Despite the fact that ribavirin is pre-
dominantly excreted by the kidneys, nephrotoxicity has
not been previously reported. In our seven postmortem
subjects, we detected no distinct renal pathology and did
not find CoV ultrastructurally. However, the ultrastruc-
tural interpretation was limited by autolysis of the tissues
and a direct involvement of the kidneys by the CoV could
not be entirely ruled out. The detection of PCR fragments
of CoV in urine from 21% to 50% of SARS patients be-
tween the second and third week of the viral infection
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Table 6. Clinical and pathologic findings of seven severe acute respiratory syndrome (SARS) patients undergoing postmortem examination
SARS Plasma
confirmed Kidney Plasma creatinine
by polymerase confirmed Viral particles creatinine at at the time Postmortem
Case chain by light Benign by electron presentation of death cause
number Gender/age reaction microscopy nephrosclerosis microscopy Autolysis lmol/L lmol/L of death
1 M/69 Yes Moderate acute + Not detected Yes 100 258 Diffuse alveolar
tubular necrosis damage
2 M/64 Yes Moderate acute + Not detected Yes 88 209 Diffuse alveolar
tubular necrosis damage
3a M/76 Yes Severe acute + Not detected Yes 153 179 Diffuse alveolar
tubular necrosis damage
4 F/81 Yes Mild acute + Not detected Minimal 107 131 Diffuse alveolar
tubular necrosis damage
5 M/44 Yes Severe acute − not detected yes 107 315 Diffuse alveolar
tubular necrosis damage
6 M/79 Yes Moderate acute + not detected yes 179 238 Diffuse alveolar
tubular necrosis damage
7 F/91 Yes Minimal + not detected yes 75 97 Diffuse alveolar
damage
aHeavy abnormal myeloid infiltrate in the kidney (the patient had history of myelodysplastic syndrome).
[16] still highlights a possibility of kidney tropism of the
CoV. Nevertheless, the normal glomerular histology with
absence of electron-dense deposits, mild proteinuria, and
absence of active cellular cast all tend to negate the exis-
tence of an active immune-mediated glomerulonephritis.
Moreover, the in situ hybridization study also failed to
detect SARS-CoV in kidney tissues and suggested that
persistent infection in these fatal cases was less likely.
On the other hand, refractory hypotension oc-
curred commonly in those patients who developed
multiorgan failures. Inotropic support in forms of
adrenaline/noradrenaline infusion was administered to
half of these patients. Bacterial sepsis, not uncommon in
these patients on prolonged ventilatory support and mul-
tiorgan failure, could also contribute to the development
of ARF. The fall in glomerular filtration secondary to
hypotension, vasoconstriction and sepsis plausibly con-
tributed to the development of acute tubular necrosis,
evidenced by the histologic finding of the renal tissues in
our study.
The poor survival of chronic dialysis patients compli-
cated by SARS was not surprising [11–13] as patients with
chronic illness recovered poorly following SARS [17, 19].
However, this cohort of patients with ARF demonstrated
an extremely poor prognosis. The mortality was in excess
of 90% and higher than those who developed ARDS re-
quiring ventilatory support. The ARF reflects that the
renal insult occurred in the context of multiorgan failure.
As our clinical findings suggest the relative importance
of prerenal factors in the development of ARF in these
SARS patients, strict precautions should be exercised
to ensure that these patients receive adequate hemody-
namic support. Hypotension and sepsis must be treated
aggressively as the complicating renal impairment is al-
ways associated with high mortality. In our multivariate
analysis, ARDS is the most significant independent risk
factors predicting the development of ARF in SARS de-
spite other parameters (systolic blood pressure, low nadir
leukocyte count, low nadir lymphocyte count, low plasma
albumin on admission, and the peak serum creatinine ki-
nase phosphatase) are implicated in the development of
ARF by univariate analysis.
CONCLUSION
ARF is uncommon in SARS yet carries a high mor-
tality. It occurs in patients complicated with acute respi-
ratory distress syndrome (ARDS) or multiorgan failure.
The development of ARF is an important negative prog-
nostic indicator for survival with SARS.
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